Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$11.24 USD
-0.32 (-2.77%)
Updated Sep 19, 2025 03:59 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Astellas Pharma Inc. has a PEG ratio of 1.70 compared to the Medical - Drugs industry's PEG ratio of 2.75.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALPMY 11.24 -0.32(-2.77%)
Will ALPMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
Other News for ALPMY
J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Astellas Pharma just downgraded at Bernstein, here's why
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer